Canada taps Tamiflu stash to help Roche meet demand; Bayer nabs FDA approval for long-term contraceptive;

@FiercePharma: That pregnancy-drug/breast cancer liability suit? All wrapped. $LLY, 4 women reach deal on 2nd day of trial. More | Follow @FiercePharma

 @AlisonBFierce: A fast and early flu season here in the U.S. The CDC's weekly flu map looks grim. More | Follow @AlisonBFierce

> Caught unprepared by a wave of illness, Canada is getting into its stash of Tamiflu because Roche ($RHHBY) is uncertain that its manufacturing and supply chain can keep up with demand. Report

> Bayer won FDA approval for its new long-term contraceptive Skyla, an intrauterine system that releases low doses of levonorgestrel. Report

> ViroPharma lost another court bid to stop generic versions of its antibiotic Vancocin, as a federal judge dismissed the drugmaker's suit against FDA. Report

> Sanofi ($SNY) tapped its chief scientific officer, Gary Nabel, to chair its strategic development and scientific advisory council, designed to bring outside science into the company. Report

> Hikma Pharmaceutical agreed to buy the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) for about $22.2 million, in an ongoing push to expand in that country. Report

> Canada's Jean Coutu Group, a pharmacy chain, saw profits grow 10% for its third quarter, lifted by strong sales at its generic drug unit Pro Doc. Report

> Sinclair IS Pharma expects first-half sales to hit £23 million ($36.9 million), up 4% year over year. Report

Medical Device News

 @FierceMedDev: GI Dynamics, Gore call off legal dogs in patent fight. Story | Follow @FierceMedDev

@MarkHFierce: A "smart socket" to connect to limb stump could lead to better prosthetic fit. U.K. scientists are doing all the work. Item | Follow @MarkHFierce

 @DamianFierce: At yesterday's FierceBiotech JPM13 panel, R&D experts debunked some Big Data myths and looked to a bright future. Editor's Corner | Follow @DamianFierce

> Ex-Orthofix manager gets home confinement in Medicare kickback case. Story

> This time, 'cautious optimism' at the J.P. Morgan Healthcare Conference. Editor's Corner

> Stryker: Hip device recalls could cost up to $390M. More

Biotech News

 @FierceBiotech: PATH, Inovio zero in on DNA malaria vaccine. News | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline commits venture $$$ to new $250M biotech startup fund--Sanderling 7, coming 9 years after the last one. Story | Follow @JohnCFierce

> Ultragenyx snags another candidate for its rare disease drug pipeline. Article

> Teva tries to slow arrival of Biogen's competing MS blockbuster. News

Pharma News

@FiercePharma: That pregnancy-drug/breast cancer liability suit? All wrapped. $LLY, 4 women reach deal on 2nd day of trial. More | Follow @FiercePharma

 @AlisonBFierce: A fast and early flu season here in the U.S. The CDC's weekly flu map looks grim. More | Follow @AlisonBFierce

> Lilly settles suit linking old miscarriage drug to breast cancer. News

> Eyeing Biogen drug, Teva demands review for new MS meds. Story

> FDA backs tech to throw off painkiller addicts. Article

> Don't expect GSK to spin off ViiV anytime soon, R&D chief says. Report

Vaccines News

> Widespread, early flu season grips United States. Item

> HPV-related cancers up despite vaccines from Merck, GSK. Story

> Altravax pulls in $1.2M from NIH. Article

> Pfizer wins Prevenar 13 expansion in EU. News

> India's vaccine prices soar as private companies gain ground. Story

Pharma Manufacturing News

> Hikma acquisition lands 2 plants in Egypt. Report

> Canada taps Tamiflu stash to help Roche meet demand. Article

> FDA inspectors come down hard on Taiwan plant. News

> More plant closings for Valeant. Story

And Finally... A nonpartisan think tank proposes cost-effectiveness measures for the U.S. healthcare system that it says could save $2 trillion over the next decade. Report

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.